Introduction: Bullous pemphigoid (BP) is an autoimmune skin disease that typically presents with severe itching and blistering, with or without eczematous and urticarial lesions. Patients with BP are at an increased risk of comorbid conditions, especially neurologic and psychiatric diseases. Several recent studies have found a link between BP and neurological disorders, especially stroke, dementia, and Parkinson's disease. The aim of our study was to evaluate the prevalence of neurological and psychiatric comorbidities and their treatment in BP patients. Methods: A cross-sectional, observational, descriptive study was conducted based on the analysis of the medical records of 105 patients with confirmed BP. Demographic and clinical data on BP, neurological and psychiatric comorbidities were collected and statistically analyzed for all patients. Results: The median age was 77.8±10.6 years (range, 39-98 years). Among the study group, 71 (67,61%) patients had neurological comorbidity. Comorbidity with the highest frequency was ischemic stroke found in 28 (26,67%) patients, followed by dementia in 27 (25,71%), Alzheimer's in 11 (10,48%) and Parkinson's disease 5 (4,76%) patients. It was noted that there was a statistically significant difference among male and female patients with Alzheimer's disease (p = 0,0046) and psychiatric disorder (p = 0,044). Conclusion: Neurological disorders usually precede the diagnosis of BP, and mortality may be higher in patients with comorbid conditions. Clinicians should be aware of the early signs and symptoms of BP, primarily in patients with primary neurological disorders such as dementia, stroke, or Parkinson's disease.
References
1.
Casas-de-la-Asunción E, Ruano-Ruiz J, Rodríguez-Martín AM, Vélez García-Nieto A, Moreno-Giménez JC. Association Between Bullous Pemphigoid and Neurologic Diseases: A Case-Control Study. Actas Dermo-Sifiliográficas (English Edition). 2014;105(9):860–5.
2.
Rania M, Petersen LV, Benros ME, Liu Z, Diaz L, Bulik CM. Psychiatric comorbidity in individuals with bullous pemphigoid and all bullous disorders in the Danish national registers. BMC Psychiatry. 2020;20(1).
3.
Försti AK, Jokelainen J, Ansakorpi H, Seppänen A, Majamaa K, Timonen M, et al. Psychiatric and neurological disorders are associated with bullous pemphigoid – a nationwide Finnish Care Register study. Scientific Reports. 6(1).
4.
Kibsgaard L, Rasmussen M, Lamberg A, Deleuran M, Olesen AB, Vestergaard C. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. British Journal of Dermatology. 2017;176(6):1486–91.
5.
Försti A, Huilaja L, Schmidt E, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid—more than skin deep? Experimental Dermatology. 2017;26(12):1228–34.
6.
Milani-Nejad N, Zhang M, Kaffenberger J. The association between bullous pemphigoid and neurological disorders: a systematic review. European Journal of Dermatology. 2017;27(5):472–81.
7.
Papakonstantinou E, Limberg MM, Gehring M, Kotnik N, Kapp A, Gibbs BF, et al. Neurological disorders are associated with bullous pemphigoid. Journal of the European Academy of Dermatology and Venereology. 2019;33(5):925–9.
8.
Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. British Journal of Dermatology. 2011;165(3):593–9.
9.
Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2016;30(12):2007–15.
10.
Kwan Z, Lai YN, Ch’ng CC. The association between bullous pemphigoid and neurological disorders in a selected Malaysian population. Med J Malaysia. 2015;70:81–5.
11.
Kulthanan K, Chularojanamontri L, Tuchinda P. Prevalence and clinical features of Thai patients with bullous pemphigoid. Asian Pac J Allergy Immunol. 2011;29:66–72.
12.
Teixeira VB, Cabral R, Brites MM, Vieira R, Figueiredo A. Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients. Anais Brasileiros de Dermatologia. 2014;89(2):274–8.
13.
Taghipour K, Chi CC, Vincent A, Groves RW, Venning V, Wojnarowska F. The Association of Bullous Pemphigoid With Cerebrovascular Disease and Dementia. Archives of Dermatology. 2010;146(11).
14.
Foureur N, Descamps V, Lebrun-Vignes B. Bullous pemphigoid in a leg affected with hemiparesia: a possible relation of neurological diseases with bullous pemphigoid? Eur J Dermatol. 2001;11:230–3.
15.
Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The Associations Between Bullous Pemphigoid and Drug Use. JAMA Dermatology. 2013;149(1):58.
16.
Schmidt E, Zillikens D. Pemphigoid diseases. The Lancet. 2013;381(9863):320–32.
17.
Brick KE, Weaver CH, Savica R, Lohse CM, Pittelkow MR, Boeve BF, et al. A population-based study of the association between bullous pemphigoid and neurologic disorders. Journal of the American Academy of Dermatology. 2014;71(6):1191–7.
18.
Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, et al. Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case–Control Study. Journal of Investigative Dermatology. 2011;131(3):637–43.
19.
Dimitrovski T. Investigation for national readiness for e-Health in South East European country: technology acceptance for electronic health records. White Rose e-Thesis online. 2018;
20.
Daniel BS, Murrell DF. Review of autoimmune blistering diseases: the Pemphigoid diseases. Journal of the European Academy of Dermatology and Venereology. 2019;33(9):1685–94.
21.
Lynch-Godrei A, Kothary R. Functional and Genetic Analysis of Neuronal Isoforms of BPAG1. Methods in Enzymology. 2016. p. 355–72.
22.
Künzli K, Favre B, Chofflon M, Borradori L. One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1. Experimental Dermatology. 2016;25(1):10–6.
23.
Taghipour K, Chi C ‐C., Bhogal B, Groves RW, Venning V, Wojnarowska F. Immunopathological characteristics of patients with bullous pemphigoid and neurological disease. Journal of the European Academy of Dermatology and Venereology. 2014;28(5):569–73.
24.
Langan SM, Groves RW, West J. The Relationship between Neurological Disease and Bullous Pemphigoid: A Population-Based Case–Control Study. Journal of Investigative Dermatology. 2011;131(3):631–6.
25.
Bucciarelli P, Balice Y, Cianchini G, Quaglino P, Pinton PC, Caproni M, et al. Increased risk of venous thromboembolism in patients with bullous pemphigoid. Thrombosis and Haemostasis. 2016;115(01):193–9.
26.
Pankakoski A, Sintonen H, Ranki A, Kluger N. Comorbidities of bullous pemphigoid in a Finnish cohort. European Journal of Dermatology. 2018;28(2):157–61.
27.
Bech R, Kibsgaard L, Vestergaard C. Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature. Frontiers in Medicine. 5.
28.
Jedlickova H, Hlubinka M, Pavlik T, Semradova V, Budinska E, Vlasin Z. Bullous pemphigoid and internal diseases – A case-control study. European Journal of Dermatology. 2010;20(1):096–101.
29.
Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. British Journal of Dermatology. 2009;161(4):861–8.
30.
Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmunity Reviews. 2014;13(4–5):477–81.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
